Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Loosli TMoore CBBuzaalirwa LByakwaga HÇelikağ İChimbetete CEbasone PVGiandhari JHan NHuwa JKasozi CMafoua AMessou EMinga AMuula GMuyindike WNdala ACMSauermann MSemeere ASingh LKouyos RDLessells REgger M2025-05-232025-May-210.1093/cid/ciaf204https://pubs.cidrz.org/handle/123456789/10190Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.